BILLERICA, Mass.--(

马萨诸塞州比勒里卡--(

BUSINESS WIRE

商业热线

)--

)--

Quanterix Corporation

Quanterix公司

(NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that David R. Walt, co-inventor of the Company’s Simoa technology has received the National Medal of Technology and Innovation, bestowed by the President of the United States.

（纳斯达克：QTRX），一家通过超灵敏生物标志物检测推动科学发现的公司，今天宣布，该公司Simoa技术的共同发明人David R.Walt获得了美国总统授予的国家技术与创新奖章。

Since it was first awarded in 1985, the National Medal of Technology and Innovation has recognized American innovators whose vision, intellect, creativity, and determination have strengthened America’s economy and improved our quality of life. The medal was established by Congress in 1980 and is administered by the U.S.

自1985年首次颁发国家技术与创新奖章以来，它表彰了美国的创新者，他们的远见、才智、创造力和决心加强了美国的经济，提高了我们的生活质量。该奖章由国会于1980年设立，由美国管理。

Patent and Trademark Office..

专利商标局。。

The Medal is awarded to individuals, teams, companies or divisions of companies for their outstanding contributions to America’s economic, environmental and social well-being. The purpose of the National Medal of Technology and Innovation is to recognize those who have made lasting contributions to America's competitiveness, standard of living, and quality of life through technological innovation, and to recognize those who have made substantial contributions to strengthening the nation's technological workforce..

该奖章授予个人、团队、公司或公司部门，以表彰他们对美国经济、环境和社会福祉的杰出贡献。国家技术与创新奖章的目的是表彰那些通过技术创新为美国竞争力、生活水平和生活质量做出持久贡献的人，并表彰那些为加强国家技术劳动力队伍做出重大贡献的人。。

“We are thrilled that David has received the prestigious honor of the National Medal of Technology and Innovation,” said Masoud Toloue, President and CEO of Quanterix. “This award is not only a testament to David and his lifelong work, but also demonstrates the power of Simoa in detecting disease early, before symptoms appear, using non-invasive methods.

Quanterix总裁兼首席执行官马苏德·托卢伊（MasoudToloue）表示：“我们很高兴大卫获得了国家技术与创新奖章的殊荣。这个奖项不仅是对大卫及其终身工作的证明，而且也证明了Simoa在症状出现之前使用非侵入性方法早期发现疾病的能力。

Our best-in-class technology has established Quanterix as a leader in Neurology and we are rapidly expanding our presence in other markets such as Immunology and Oncology.”.

我们一流的技术已使Quanterix成为神经病学领域的领导者，我们正在迅速扩大在免疫学和肿瘤学等其他市场的影响力。”。

To learn more about Quanterix, visit

要了解有关Quanterix的更多信息，请访问

www.quanterix.com/company

www.quanterix.com/company

. To learn more about Quanterix’s Simoa® technology, visit

。要了解有关Quanterix Simoa®技术的更多信息，请访问

www.quanterix.com/simoa-technology

.

.

About Quanterix

关于Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ).

从发现到诊断，Quanterix的超灵敏生物标志物检测正在推动突破，只有通过其无与伦比的灵敏度和灵活性才能实现。该公司的Simoa®技术为血液，血清或血浆中的早期生物标志物检测提供了金标准，能够量化远低于定量水平（LoQ）的蛋白质。

Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,100 peer-reviewed journals.

其业界领先的精密仪器、数字免疫分析技术和CLIA认证的加速器实验室支持了促进神经病学、肿瘤学、免疫学、心脏病学和传染病疾病理解和管理的研究。近二十年来，Quanterix一直是科学界值得信赖的合作伙伴，为3100多种同行评审期刊上发表的研究提供了动力。

Find additional information about the Billerica, Massachusetts-based company at .

有关这家位于马萨诸塞州Billerica的公司的更多信息，请访问。

https://www.quanterix.com

https://www.quanterix.com

or follow us on

或者继续关注我们

Twitter

推特

and

和

LinkedIn

LinkedIn

.

.